Octavio Espinoza - 04 Mar 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol
LGND
Transactions as of
04 Mar 2026
Net transactions value
-$2,762,822
Form type
4
Filing time
06 Mar 2026, 18:49:54 UTC
Previous filing
18 Feb 2026
Next filing
13 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Espinoza Octavio Chief Financial Officer 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 06 Mar 2026 0001905248

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise +1,607 +4.9% $58.49* 34,619 04 Mar 2026 Direct F1
transaction LGND Common Stock Options Exercise +466 +1.3% $80.72* 35,085 04 Mar 2026 Direct F1
transaction LGND Common Stock Sale $138,895 -699 -2% $198.71 34,386 04 Mar 2026 Direct F1, F2
transaction LGND Common Stock Sale $10,604 -53 -0.15% $200.08 34,333 04 Mar 2026 Direct F1, F3
transaction LGND Common Stock Sale $140,364 -698 -2% $201.09 33,635 04 Mar 2026 Direct F1, F4
transaction LGND Common Stock Sale $191,640 -950 -2.8% $201.73 32,685 04 Mar 2026 Direct F1, F5
transaction LGND Common Stock Sale $141,343 -697 -2.1% $202.79 31,988 04 Mar 2026 Direct F1, F6
transaction LGND Common Stock Sale $136,024 -668 -2.1% $203.63 31,320 04 Mar 2026 Direct F1, F7
transaction LGND Common Stock Sale $152,125 -743 -2.4% $204.74 30,577 04 Mar 2026 Direct F1, F8
transaction LGND Common Stock Sale $299,841 -1,457 -4.8% $205.79 29,120 04 Mar 2026 Direct F1, F9
transaction LGND Common Stock Sale $328,542 -1,588 -5.5% $206.89 27,532 04 Mar 2026 Direct F1, F10
transaction LGND Common Stock Sale $510,823 -2,457 -8.9% $207.91 25,075 04 Mar 2026 Direct F1, F11
transaction LGND Common Stock Sale $712,621 -3,413 -14% $208.80 21,662 04 Mar 2026 Direct F1, F12

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise -1,607 -100% $0.000000* 0 04 Mar 2026 Common Stock 1,607 $58.49 Direct F1, F13
transaction LGND Employee Stock Option (right to buy) Options Exercise -466 -100% $0.000000* 0 04 Mar 2026 Common Stock 466 $80.72 Direct F1, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.3700 to $199.2500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4400 to $200.0900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.5000 to $201.3400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.4600 to $202.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.4000 to $203.0500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $203.4100 to $203.8600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.4600 to $205.3600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $205.3700 to $206.3600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $206.4700 to $207.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $207.4100 to $208.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $208.3900 to $208.9500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F13 The stock option is fully vested and exercisable.